In vivo CAR-T shows promise—but only in mice, for now

Azalea Therapeutics has demonstrated something long sought in cancer research: CAR-T cells engineered in vivo—directly inside the body—using precise gene editing. The study, published in Nature Biotechnology, showed these modified cells successfully cleared tumors in mice, a result that aligns with the core promise of CAR-T therapy but sidesteps its logistical hurdles.

Current CAR-T treatments require extracting a patient’s immune cells, reengineering them in a lab, and reinfusing them—a process that is costly, time-consuming, and inaccessible to many. Azalea’s approach, if replicated in humans, could theoretically simplify this. But the leap from mouse models to clinical reality is notoriously fraught.

The study’s methodology relied on lipid nanoparticles to deliver gene-editing tools (CRISPR-Cas9) and CAR-T constructs directly to T cells in the mice. This is a technical feat, but one with critical constraints: the sample size was small, the mice were genetically uniform, and the tumor models don’t fully replicate human cancer complexity. As Dr. Carl June, a pioneer in CAR-T therapy, noted in unrelated work, ‘Mouse cures have been a graveyard for human hopes.’

For patients today, this research changes nothing. CAR-T remains an FDA-approved but highly specialized treatment, reserved for specific blood cancers and administered in controlled clinical settings. The in vivo approach, while elegant in theory, hasn’t entered human trials—let alone demonstrated safety or efficacy outside a lab.

The cost and access arguments are equally premature. Speculation that this method could ‘expand access’ assumes it will work in humans, scale affordably, and clear regulatory hurdles—none of which are guaranteed. Even if successful, the manufacturing challenges of lipid nanoparticle delivery at scale are substantial.

What the study does prove is that in vivo CAR-T engineering is biologically plausible. That’s a meaningful step, but it’s just one step. The next phases—testing in larger animals, then early-stage human trials—will reveal whether this is a viable path or another dead end in the long road to better cancer therapies.